WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 12, 419-437. Review Article ISSN 2277–7105

LINALOOL AS ADJUNCTIVE ANTIEPILEPTIC THERAPY: A REVIEW ON NOSE TO BRAIN DRUG DELIVERY

Sakshi S. Wattamwar*, Divya C. Meshram, Tejal A. Mujmule, Utkarsha S. Mujmule, Prof. Satwik V. Jadhao and Dr. Manisha D. Kitukale

P. Wadhwani College of Pharmacy, Yavatmal.

Article Received on 15 May 2026,
Article Revised on 05 June 2026,
Article Published on 16 June 2026
https://doi.org/10.5281/zenodo.20696002

***Corresponding Author**
Sakshi S. Wattamwar
P. Wadhwani College of Pharmacy, Yavatmal.

How to cite this Article: Sakshi S. Wattamwar*, Divya C. Meshram, Tejal A. Mujmule, Utkarsha S. Mujmule, Prof. Satwik V. Jadhao and Dr. Manisha D. Kitukale. (2026). Linalool as Adjunctive Antiepileptic Therapy: A Review on Nose to Brain Drug Delivery. World Journal of Pharmaceutical Research, 15(12), 419–437.

ABSTRACT

Epilepsy is a multifactorial neurological disorder characterized by recurrent seizures resulting from aberrant neuronal discharge and impaired synaptic regulation within the central nervous system. Although currently available antiepileptic drugs provide symptomatic seizure suppression, their therapeutic utility is frequently compromised by pharmacoresistance, systemic toxicity, neurocognitive adverse effects, and restricted permeability across the blood–brain barrier. Consequently, the development of alternative brain-targeted therapeutic strategies has emerged as a significant area of neuropharmaceutical research. The present review systematically examines the therapeutic relevance of linalool, a naturally occurring bioactive monoterpene, as a potential adjunctive antiepileptic agent administered through the intranasal nose-to-brain pathway. Preclinical investigations have demonstrated that linalool exerts anticonvulsant and neuroprotective effects through modulation of GABAergic inhibitory signaling, attenuation of glutamatergic excitotoxicity, suppression of neuroinflammatory mediators, and reduction of oxidative neuronal damage. Intranasal administration facilitates rapid and direct transport of linalool to the brain via olfactory and trigeminal neural pathways, thereby circumventing the blood–brain barrier and hepatic first-pass metabolism. Furthermore, advanced nanoformulation-based delivery systems have shown enhanced nasal permeation, improved cerebral bioavailability, prolonged drug retention, and sustained therapeutic activity. Despite promising experimental outcomes, translational limitations persist due to inadequate clinical validation, variability in formulation strategies, insufficient pharmacokinetic characterization, and concerns regarding long-term safety and formulation stability. Collectively, the available scientific evidence supports the potential applicability of intranasal linalool delivery as an innovative adjunctive therapeutic approach for epilepsy management. Nevertheless, comprehensive clinical investigations and formulation standardization studies remain essential for establishing its therapeutic efficacy, safety profile, and future clinical applicability.

KEYWORDS: Epilepsy; Linalool; Intranasal delivery; Nose-to-brain targeting; Anticonvulsant activity; Neuroprotection; Blood–brain barrier; Nanoformulations; Central nervous system; Adjunctive therapy.

INTRODUCTION

The review project is based on published scientific literature, experimental model and methodologies discussed in this sector are compiled from previously reported antiepileptic studies for academic and comparative understanding.

Epilepsy is a long-term neurological condition where the brain has a tendency to experience repeated seizures without a clear cause. This disorder can develop due to brain injuries like head trauma, strokes, infections, or tumors, or it can be caused by genetic changes that affect how neurons function, including ion channels, neurotransmitters, and the brain's ability to control electrical activity. It is one of the most widespread neurological conditions globally, affecting almost 50 million people, with about 1% of the world's population developing it at some point in their lives.[1]

In 2005, the International League Against Epilepsy (ILAE) described epilepsy as a lasting condition where the brain has an increased likelihood of having seizures, which can lead to various biological, mental, emotional, and social challenges.[2]

In addition to seizures, epilepsy can greatly affect a person's daily life and place a heavy burden on both patients and their families. Even with improvements in diagnosing and treating epilepsy, there is still a significant gap in care, especially in poorer countries, because of limited access to healthcare and insufficient treatment options.[3]

❖ Types Of Epilepsy

Type of Epilepsy	Subtype	Features
Focal Epilepsy	Focal Aware Seizure Focal Impaired Awareness Seizure Focal to Bilateral Tonic–Clonic Seizure	Awareness remains intact with sensory or motor symptoms. Altered consciousness with automatisms and confusion. Begins focally and spreads to both hemispheres causing convulsions.
Generalized Epilepsy	Absence Seizure Tonic–Clonic Seizure Myoclonic Seizure Atonic Seizure Tonic Seizure Clonic Seizure	Brief staring episodes with temporary loss of awareness. Muscle stiffening followed by rhythmic jerking movements. Sudden, brief muscle jerks. Sudden loss of muscle tone resulting in falls. Sudden muscle stiffness and rigidity. Repetitive rhythmic jerking of muscles
Combined Generalized and Focal Epilepsy	Mixed Seizure Type	Features of both focal and generalized seizures are present.

❖ Treatment Of Seizure/Epilepsy

Drug	Mechanism Of Action (MOA)	Uses	Major Adverse Drug Reactions (ADRs)
Valproate	Increases GABA levels and blocks sodium channels.	Generalized seizures, absence seizures, bipolar disorder, migraine prophylaxis.	Hepatotoxicity, weight gain, tremors, teratogenicity.
Phenytoin	Blocks voltage-gated sodium channels.	Tonic–clonic and focal seizures, status epilepticus.	Gingival hyperplasia, ataxia, hirsutism, megaloblastic anemia
Carbamazepine	Stabilizes inactive sodium channels and reduces neuronal firing.	Focal seizures, tonic–clonic seizures, trigeminal neuralgia.	Dizziness, diplopia, hyponatremia, aplastic anemia.
Phenobarbital	Enhances GABA-mediated CNS inhibition.	Generalized and focal seizures, neonatal seizures.	Sedation, cognitive impairment, dependence, respiratory depression.

Need Of Antiepileptic Drugs

Conventional antiepileptic drugs (AEDs) are often limited by inadequate seizure control, systemic toxicity, poor blood–brain barrier penetration, and significant neurological adverse effects. Consequently, there is a growing demand for novel adjunctive therapies with improved safety and therapeutic efficacy.[5] Linalool, a bioactive monoterpene, has demonstrated anticonvulsant, neuroprotective, and anxiolytic potential in preclinical studies. Intranasal nose-to-brain delivery offers a direct pathway to the central nervous system, bypassing the blood–brain barrier and enhancing cerebral drug bioavailability. Therefore, linalool administered via the nose-to-brain route may serve as a promising adjunctive antiepileptic strategy for enhanced seizure management with reduced systemic side effects.[6]

❖ OBJECTIVE OF REVIEW

The objective of this review is to critically examine the therapeutic potential of linalool as an adjunctive antiepileptic agent and to explore the significance of nose-to-brain drug delivery in enhancing central nervous system bioavailability, improving seizure control, and minimizing systemic adverse effects associated with conventional antiepileptic therapy.

❖ LINALOOL

Linalool is a naturally occurring monoterpene alcohol with significant anticonvulsant, neuroprotective, anxiolytic, and antioxidant properties.[7] It modulates GABAergic and glutamatergic neurotransmission, thereby reducing neuronal hyperexcitability associated with epilepsy.[8] However, its therapeutic efficacy is limited by poor bioavailability and restricted blood–brain barrier penetration.[9] Intranasal nose-to-brain delivery provides a direct pathway to the central nervous system, enhancing cerebral drug targeting, improving therapeutic effectiveness, and minimizing systemic adverse effects, thereby supporting the potential of linalool as an adjunctive antiepileptic agent.[10]



LINALOOL

Structure	Molecular weight	solubility	Boiling point
	154.25 g/mol	Poorly soluble in water; soluble in organic solvents	198–200 °C

Mechanism of Anticonvulsant Action of Linalool

Anticonvulsant Action of Linalool

GABAergic Modulation	Glutamatergic Inhibition	NMDA Receptor Blockade
↑ GABA-mediated inhibitory neurotransmission	↓ Glutamate release and excitatory signaling	↓ NMDA receptor activation

Reduced Neuronal Hyperexcitability

↓

Suppression of Seizure Activity

↓

Anticonvulsant Effect of Linalool[11]

NOSE TO BRAIN DELIVERY OF LINALOOL



Mechanism Of Brain Targeting

Intranasal Administration

|

Nasal Cavity Deposition

|

Olfactory Pathway | Trigeminal Pathway

Transport through olfactory neurons and epithelium | Transport through trigeminal nerve endings

Direct Nose-to-Brain Transport

|

Bypass of Blood–Brain Barrier

|

Rapid Drug Distribution in CNS

|

Increased Brain Bioavailability

|

Enhanced Anticonvulsant Activity[20]

Intranasal administration enables direct transport of therapeutic agents from the nasal cavity to the brain through the olfactory and trigeminal neural pathways, thereby facilitating rapid central nervous system delivery.[21][21] This pathway bypasses the blood–brain barrier, enhances brain bioavailability, and improves the therapeutic efficacy of anticonvulsant agents such as linalool.[22]

NEED OF STUDY

Epilepsy remains one of the most prevalent chronic neurological disorders worldwide and continues to present substantial therapeutic challenges despite significant advancements in antiepileptic pharmacotherapy. Conventional antiepileptic drugs are frequently associated with incomplete seizure control, drug resistance, systemic toxicity, cognitive impairment, and undesirable neurological adverse effects. In addition, limited permeability across the blood–

brain barrier significantly reduces the efficiency of many therapeutic agents in achieving adequate brain concentrations. These limitations necessitate the development of innovative therapeutic approaches with improved brain targeting, enhanced therapeutic efficacy, and reduced systemic exposure.

Linalool, a naturally occurring monoterpene, has attracted growing scientific interest due to its demonstrated anticonvulsant, neuroprotective, antioxidant, and anti-inflammatory properties in experimental studies. Its ability to modulate GABAergic and glutamatergic neurotransmission suggests potential utility in suppressing neuronal hyperexcitability associated with epileptic seizures. However, the clinical applicability of linalool remains restricted because of poor aqueous solubility, limited bioavailability, and inadequate penetration into the central nervous system.

Intranasal nose-to-brain drug delivery has emerged as a promising non-invasive strategy for direct brain targeting through olfactory and trigeminal neural pathways, thereby bypassing the blood–brain barrier and hepatic first-pass metabolism. This delivery approach may enhance cerebral bioavailability, improve therapeutic onset, and minimize systemic adverse effects. Therefore, the present study is necessary to critically evaluate the therapeutic potential of linalool administered through the nose-to-brain pathway as an adjunctive antiepileptic strategy and to assess its possible role in improving seizure management and neurological outcomes.

LITERATURE REVIEW

1. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 2005; 46(4): 470–2.
   This study established standardized definitions for epileptic seizures and epilepsy, improving diagnostic consistency and clinical classification. The report also highlighted the importance of accurate seizure identification in neurological research and therapeutic management.
2. Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol. Rev., 2020; 72(3): 606–38.
   The review discussed the major mechanisms responsible for pharmacoresistant epilepsy, including altered drug transporters and neuronal network modifications. The authors

emphasized the need for innovative therapeutic approaches for patients unresponsive to conventional antiepileptic drugs.

3. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat. Rev. Neurol., 2011; 7(1): 31–40.

   This review demonstrated the significant involvement of neuroinflammation in seizure generation and epileptogenesis. Inflammatory mediators were reported to contribute to neuronal excitability and progression of epilepsy.

4. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet. Neurol., 2011; 10(5): 446–56.

   The article reviewed available antiepileptic therapies and their clinical effectiveness in adult epilepsy management. Limitations such as adverse effects, drug interactions, and incomplete seizure control were also highlighted.

5. Kanner AM. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: a review of the evidence. Epilepsy. Behav., 2016; 61: 282–6.

   The review evaluated the safety profile of antidepressants in epileptic patients and suggested that most agents are relatively safe at therapeutic doses. The findings supported cautious but effective management of psychiatric comorbidities in epilepsy.

6. Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs, 2021; 35(9): 935–63.

   This article summarized the evolution of antiseizure medications and their mechanisms of action. Despite therapeutic advancements, drug-resistant epilepsy and adverse reactions remained major clinical concerns.

7. Elisabetsky E, Brum LF, Souza DO. Anticonvulsant properties of linalool in glutamate-related seizure models. Phytomedicine. 1999; 6(2): 107–13.

   The study demonstrated significant anticonvulsant activity of linalool in experimental seizure models. Linalool reduced seizure severity through modulation of glutamatergic neurotransmission.

8. Silva Brum LF, Emanuelli T, Souza DO, Elisabetsky E. Effects of linalool on glutamate release and uptake in mouse cortical synaptosomes. Neurochem. Res., 2001; 26(3): 191–4.

   This investigation reported that linalool influences glutamate release and uptake in neuronal tissues. The findings suggested its potential role in regulating excitatory neurotransmission associated with seizures.

9. Peana AT, D'Aquila PS, Panin F, Serra G, Pippia P, Moretti MDL. Anti-inflammatory activity of linalool and linalyl acetate constituents of essential oils. Phytomedicine, 2002; 9(8): 721–6.

The study identified significant anti-inflammatory activity of linalool and related compounds. These pharmacological properties may contribute to neuroprotection in neurological disorders.

10. Linck VM, da Silva AL, Figueiró M, Caramão EB, Moreno PRH, Elisabetsky E. Effects of inhaled linalool in anxiety, social interaction and aggressive behavior in mice. Phytomedicine, 2009; 16(4): 303–7.

The authors demonstrated behavioral and anxiolytic effects of inhaled linalool in experimental animals. The findings supported the central nervous system activity of linalool following inhalational exposure.

11. De Sousa DP. Analgesic-like activity of essential oils constituents. Molecules, 2011; 16(3): 2233–52.

This review summarized the pharmacological activities of essential oil constituents including linalool. Analgesic, anti-inflammatory, and neuroactive effects were extensively discussed.

12. Cunha MP, Pazini FL, Oliveira A, Rosa JM, Ramos-Hryb AB, Brocardo PS, et al. The antidepressant-like effect of linalool in a mouse model. Behav. Brain. Res., 2013; 237: 1–7.

The study demonstrated antidepressant-like activity of linalool in experimental models. Neuroprotective and neuromodulatory mechanisms were suggested as contributing factors.

13. Illum L. Nasal drug delivery—possibilities, problems and solutions. J Control Release, 2003; 87(1–3): 187–98.

This review discussed the advantages and limitations of nasal drug delivery systems. Intranasal administration was identified as a promising route for brain targeting and rapid therapeutic action.

14. Hanson LR, Frey WH. Intranasal delivery bypasses the blood–brain barrier to target therapeutic agents to the central nervous system. BMC Neurosci., 2008; 9(3): S5.

The study demonstrated that intranasal administration enables direct delivery of therapeutic agents to the brain while bypassing the blood–brain barrier. This route may improve central nervous system drug bioavailability.

15. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv. Drug. Deliv. Rev., 2012; 64(7): 614–28.

    The review highlighted the therapeutic potential of intranasal drug delivery for neurological disorders. Direct nose-to-brain transport pathways were discussed in detail.

16. Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting. Expert. Opin. Drug. Deliv., 2013; 10(7): 957–72.

    This review described the role of olfactory and trigeminal neural pathways in direct nose-to-brain drug delivery. The approach was considered effective for enhancing brain targeting while minimizing systemic exposure.

17. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv., 2014; 21(2): 75–86.

    The article discussed current advancements in intranasal brain targeting systems and their applications in neurological disorders. Challenges associated with formulation stability and delivery efficiency were also highlighted.

18. Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J. Control Release, 2017; 268: 364–89.

    This review summarized recent progress in nasal drug delivery strategies for brain targeting. Nanoformulations and carrier-based systems were reported to improve therapeutic efficacy and drug bioavailability.

19. Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res. Bull., 2018; 143: 155–70.

    The study evaluated the effectiveness of intranasal drug administration for central nervous system targeting. The findings supported the potential of nose-to-brain delivery in neurological therapy.

20. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug. Deliv. Rev., 2005; 57(11): 1640–65.

    This review emphasized the significance of mucoadhesive systems in improving nasal drug retention and absorption. Mucoadhesive formulations were reported to enhance intranasal therapeutic performance.

21. Patel MM, Patel BM. Crossing the blood–brain barrier: recent advances in drug delivery to the brain. CNS Drugs, 2017; 31(2): 109–33.

The article reviewed recent approaches for overcoming blood–brain barrier limitations in neurological drug delivery. Nanocarriers and targeted delivery systems showed improved brain uptake and therapeutic efficiency.

22. Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Hamano N, Li SD, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release, 2018; 281: 139–77.
    This review discussed clinical challenges associated with nose-to-brain delivery systems, including formulation reproducibility and regulatory limitations. The authors highlighted the growing therapeutic potential of intranasal therapies.
23. Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release, 2018; 270: 89–100.
    The study summarized non-clinical investigations involving nanotechnology-based nose-to-brain drug delivery systems. Nanoformulations demonstrated enhanced brain targeting efficiency and controlled drug release.
24. Sonvico F, Clementino A, Buttini F, Colombo G, Pescina S, Stanisçuaski Guterres S, et al. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics, 2018; 10(1): 34.
    This review highlighted the role of surface-modified nanocarriers in improving nasal adhesion and brain targeting. Functionalized nanocarriers showed enhanced drug transport through neural pathways.
25. Kulkarni AD, Bari SB. Surfactant assisted nasal drug delivery: current concepts and future perspectives. Drug. Deliv., 2015; 22(5): 559–71.
    The article discussed the importance of surfactants in improving nasal permeability and drug absorption. Surfactant-assisted formulations were considered beneficial for enhancing nose-to-brain transport.
26. Ruszkowski D, Albrecht J. Changes in the mitochondrial antioxidant systems in neurodegenerative diseases and acute brain disorders. Neurochem. Int., 2015; 88: 66–72.
    This review described the role of oxidative stress and mitochondrial dysfunction in neurological disorders. Antioxidant mechanisms were suggested as important therapeutic targets for neuroprotection.
27. De Cássia da Silveira e Sá R, Andrade LN, de Sousa DP. A review on anti-inflammatory activity of monoterpenes. Molecules, 2013; 18(1): 1227–54.

The review summarized anti-inflammatory activities of monoterpenes including linalool. These compounds demonstrated potential neuroprotective and therapeutic applications in inflammatory disorders.

28. Souto EB, Zielinska A, Souto SB, Durazzo A, Lucarini M, Santini A, et al. Nanopharmaceutics: part I—clinical trials legislation and good manufacturing practices (GMP) of nanotherapeutics in clinical practice. Int. J. Mol. Sci., 2020; 21(23): 9186.
The article reviewed regulatory and clinical considerations associated with nanotherapeutic formulations. Standardization and quality assurance were identified as important aspects for clinical translation.
29. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm., 2007; 337(1–2): 1–24.
This review discussed physicochemical factors influencing intranasal drug delivery efficiency. Formulation stability, nasal permeability, and therapeutic effectiveness were extensively analyzed.
30. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective. Drug Deliv. Transl. Res., 2013; 3(1): 42–62.
Zhe study reviewed various nasal drug delivery devices and their clinical applications. Device design and delivery performance were considered critical factors influencing therapeutic outcome.

COMPARISON

Reference	Title	Key Findings
Fisher et al., 2005	Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE).	Standardized definitions for seizures and epilepsy for clinical consistency
Löscher et al., 2020	Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options.	Identified mechanisms like transporter changes and network alterations
Vezzani et al., 2011	The role of inflammation in epilepsy.	Inflammation contributes to seizure generation and progression
Perucca & Tomson, 2011	The pharmacological treatment of epilepsy in adults.	AEDs effective but limited by side effects and resistance
Elisabetsky et al., 1999	Anticonvulsant properties of linalool in glutamate-related seizure models.	Linalool reduces glutamate-related seizure activity
Silva Brum et al., 2001	Effects of linalool on glutamate release and uptake in mouse cortical synaptosomes.	Modulates glutamate release and uptake in CNS

Linck et al., 2009	Effects of inhaled linalool in anxiety, social interaction and aggressive behavior in mice.	Shows anxiolytic and behavioral CNS effects via inhalation
Illum, 2003	Nasal drug delivery—possibilities, problems and solutions.	Nasal route enables direct brain targeting
Hanson & Frey, 2008	Intranasal delivery bypasses the blood–brain barrier to target therapeutic agents to the central nervous system.	Drugs can directly reach CNS via olfactory pathways
Pardeshi & Belgamwar, 2013	Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting.	Olfactory and trigeminal pathways enable direct transport

AIM AND OBJECTIVE

- **AIM**

Linalool as Adjunctive Antiepileptic Therapy: A Review on Nose to Brain Drug Delivery.

- **OBJECTIVE**

1. To review the anticonvulsant potential of linalool in epilepsy management.
2. To evaluate the role of the nose-to-brain pathway in enhancing central nervous system drug delivery.
3. To summarize the mechanisms underlying the antiepileptic activity of linalool.
4. To assess the therapeutic advantages of intranasal brain-targeted delivery systems in epilepsy treatment.
5. To analyze the potential of linalool as an adjunctive therapy for improving seizure control and reducing systemic adverse effects

LITERATURE RESEARCH METHODOLOGY

The present work will be conducted as a narrative literature review focusing on the potential application of linalool as an adjunctive antiepileptic agent via the nose-to-brain delivery pathway. Relevant scientific literature will be collected from electronic databases including PubMed, Science Direct, Google Scholar, Scopus and Research gate.

The literature search will be performed using combinations of the following keywords:

* Epilepsy
* Linalool
* Anticonvulsant activity
* Nose-to-brain delivery
* Intranasal drug delivery

Published research articles, review papers, and experimental studies related to anticonvulsant activity, intranasal brain targeting, and linalool pharmacology will be critically reviewed. Studies discussing mechanisms of epilepsy, limitations of conventional antiepileptic therapy, and formulation strategies for nose-to-brain delivery will also be included.

Inclusion Criteria

* Peer-reviewed scientific articles
* Experimental and review studies related to epilepsy and anticonvulsant therapy
* Studies involving linalool or linalool-containing essential oils
* Articles related to intranasal or nose-to-brain drug delivery systems
* English-language publications

Exclusion Criteria

* Duplicate publications
* Non-scientific reports and unpublished data
* Articles unrelated to neurological disorders or intranasal delivery
* Studies lacking scientific relevance to the review topic

The collected literature will be systematically analyzed to evaluate the anticonvulsant potential of linalool, its pharmacological mechanisms, and the therapeutic advantages of nose-to-brain delivery systems in epilepsy management.

EXPERIMENTAL WORK

Proposed Experimental Methodology

1. Formulation Approach

Review of published literature on intranasal formulations of linalool for CNS delivery.

Analysis of formulation strategies such as nanoemulsions and lipid-based carriers used for brain targeting.

Evaluation of approaches reported to improve stability and brain availability of linalool.

2. Characterization / Evaluation Studies

Review of reported formulation evaluation parameters from literature.

Assessment of studies involving drug release behavior and formulation stability

Analysis of physicochemical performance reported in published research.

3. Intranasal Delivery Evaluation

Review of nose-to-brain delivery pathway for linalool administration.

Evaluation of nasal absorption and transport through olfactory and trigeminal routes.

Analysis of literature describing enhanced brain targeting via intranasal route.

Assessment of factors influencing nasal delivery efficiency such as residence time and permeability.

4. Anticonvulsant Evaluation

Review of experimental studies on anticonvulsant activity of linalool.

Analysis of seizure models reported in literature.

Evaluation of neuroprotective and anticonvulsant mechanisms from published data.

Comparison of reported effects with conventional antiepileptic approaches.

5. Safety Assessment

Review of toxicological and safety data of linalool from published studies.

Evaluation of nasal safety and mucosal compatibility reports.

Assessment of systemic toxicity and biocompatibility findings.

Analysis of suitability for repeated or long-term administration.

6. Statistical Analysis

Qualitative synthesis of collected literature.

Comparative evaluation of findings from different studies.

Systematic summarization and presentation of data in descriptive form.

Interpretation of results based on reported outcomes in previous research.

REVIEW FINDINGS AND DISCUSSION

- The reviewed studies suggest that linalool exhibits significant anticonvulsant and neuroprotective activity, indicating its potential role as an adjunctive antiepileptic agent. Experimental evidence demonstrated that linalool reduces neuronal hyperexcitability, delays seizure onset, and decreases seizure severity through modulation of GABAergic and glutamatergic neurotransmission. In addition, its antioxidant and anti-inflammatory properties may contribute to protection against oxidative stress–induced neuronal damage associated with epilepsy.

- Several studies further reported that intranasal nose-to-brain delivery improves direct brain targeting of linalool by bypassing the blood–brain barrier and hepatic first-pass metabolism. Nanoformulations and nanoemulsion-based systems enhanced brain bioavailability, nasal permeation, formulation stability, and sustained drug release. These findings suggest that intranasal linalool administration may provide rapid therapeutic action, improved seizure control, and better patient compliance through a non-invasive delivery route.

- However, important limitations were identified in the reviewed literature. Most studies were limited to animal models and preclinical investigations, highlighting a major translational gap between experimental outcomes and clinical application in humans. Considerable variability was observed in dosage regimens, formulation methods, and seizure models, leading to dose inconsistency and lack of standardization across studies. Furthermore, insufficient pharmacokinetic and toxicity data remain a concern. The absence of well-designed human clinical trials limits the establishment of long-term safety, efficacy, and therapeutic reliability of intranasal linalool formulations. In addition, poor aqueous solubility, high volatility, and possible nasal mucosal irritation may affect formulation stability and reproducibility.

- Therefore, further standardized studies and clinical investigations are required to validate the therapeutic potential of linalool via the nose-to-brain pathway in epilepsy management.

CONCLUSION

The reviewed studies indicate that linalool possesses promising anticonvulsant and neuroprotective potential, supporting its possible application as an adjunctive antiepileptic agent through the nose-to-brain pathway. Intranasal delivery may enhance direct brain targeting and improve therapeutic efficacy while minimizing systemic limitations. However, the current evidence remains largely preclinical, with significant challenges related to dose standardization, formulation variability, translational applicability, and lack of clinical trials. Therefore, further well-designed experimental and clinical investigations are necessary to establish the safety and therapeutic relevance of intranasal linalool in epilepsy management.

Future Perspectives

Future investigations should prioritize well-structured human clinical trials to validate the therapeutic efficacy, safety, and clinical applicability of intranasal linalool formulations in epilepsy treatment. Further research is also required for optimization of nanoformulation-based delivery systems to enhance physicochemical stability, nasal retention, controlled release, and targeted brain delivery. Comprehensive pharmacokinetic and biodistribution studies remain essential to elucidate the absorption profile, brain uptake, metabolism, and elimination of linalool following intranasal administration. Additionally, long-term toxicity and safety assessments should be conducted to evaluate potential mucosal irritation, neurotoxicity, and systemic adverse effects associated with chronic exposure. Regulatory aspects including formulation standardization, quality assurance, and clinical validation should also be addressed to facilitate future regulatory approval and successful translational development of linalool-based nose-to-brain therapeutic systems.

REFERENCE

1. Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia, 2005; 46(4): 470–2.
2. Löscher W, Potschka H, Sisodiya SM, Vezzani A. Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol. Rev., 2020; 72(3): 606–38.
3. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat. Rev. Neurol., 2011; 7(1): 31–40.
4. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet. Neurol., 2011; 10(5): 446–56.
5. Kanner AM. Most antidepressant drugs are safe for patients with epilepsy at therapeutic doses: a review of the evidence. Epilepsy Behav., 2016; 61: 282–6.
6. Löscher W, Klein P. The pharmacology and clinical efficacy of antiseizure medications: from bromide salts to cenobamate and beyond. CNS Drugs, 2021; 35(9): 935–63.
7. Elisabetsky E, Brum LF, Souza DO. Anticonvulsant properties of linalool in glutamate-related seizure models. Phytomedicine. 1999; 6(2): 107–13.
8. Silva Brum LF, Emanuelli T, Souza DO, Elisabetsky E. Effects of linalool on glutamate release and uptake in mouse cortical synaptosomes. Neurochem. Res., 2001; 26(3): 191–4.
9. Peana AT, D'Aquila PS, Panin F, Serra G, Pippia P, Moretti MDL. Anti-inflammatory activity of linalool and linalyl acetate constituents of essential oils. Phytomedicine, 2002; 9(8): 721–6.

10. Linck VM, da Silva AL, Figueiró M, Caramão EB, Moreno PRH, Elisabetsky E. Effects of inhaled linalool in anxiety, social interaction and aggressive behavior in mice. Phytomedicine, 2009; 16(4): 303–7.
11. De Sousa DP. Analgesic-like activity of essential oils constituents. Molecules, 2011; 16(3): 2233–52.
12. Cunha MP, Pazini FL, Oliveira A, Rosa JM, Ramos-Hryb AB, Brocardo PS, et al. The antidepressant-like effect of linalool in a mouse model. Behav. Brain Res., 2013; 237: 1–7.
13. Illum L. Nasal drug delivery—possibilities, problems and solutions. J. Control Release, 2003; 87(1–3): 187–98.
14. Hanson LR, Frey WH. Intranasal delivery bypasses the blood–brain barrier to target therapeutic agents to the central nervous system. BMC Neurosci., 2008; 9(3): S5.
15. Lochhead JJ, Thorne RG. Intranasal delivery of biologics to the central nervous system. Adv. Drug. Deliv. Rev., 2012; 64(7): 614–28.
16. Pardeshi CV, Belgamwar VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting. Expert. Opin. Drug. Deliv., 2013; 10(7): 957–72.
17. Mittal D, Ali A, Md S, Baboota S, Sahni JK, Ali J. Insights into direct nose to brain delivery: current status and future perspective. Drug. Deliv., 2014; 21(2): 75–86.
18. Khan AR, Liu M, Khan MW, Zhai G. Progress in brain targeting drug delivery system by nasal route. J Control Release, 2017; 268: 364–89.
19. Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain. Res. Bull., 2018; 143: 155–70.
20. Ugwoke MI, Agu RU, Verbeke N, Kinget R. Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. Adv. Drug. Deliv. Rev., 2005; 57(11): 1640–65.
21. Patel MM, Patel BM. Crossing the blood–brain barrier: recent advances in drug delivery to the brain. CNS Drugs, 2017; 31(2): 109–33.
22. Agrawal M, Saraf S, Saraf S, Antimisiaris SG, Hamano N, Li SD, et al. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release, 2018; 281: 139–77.
23. Pires PC, Santos AO. Nanosystems in nose-to-brain drug delivery: a review of non-clinical brain targeting studies. J Control Release, 2018; 270: 89–100.

24. Sonvico F, Clementino A, Buttini F, Colombo G, Pescina S, Stanisçuaski Guterres S, et al. Surface-modified nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics, 2018; 10(1): 34.
25. Kulkarni AD, Bari SB. Surfactant assisted nasal drug delivery: current concepts and future perspectives. Drug Deliv., 2015; 22(5): 559–71.
26. Ruszkowski D, Albrecht J. Changes in the mitochondrial antioxidant systems in neurodegenerative diseases and acute brain disorders. Neurochem, Int., 2015; 88: 66–72.
27. de Cássia da Silveira e Sá R, Andrade LN, de Sousa DP. A review on anti-inflammatory activity of monoterpenes. Molecules, 2013; 18(1): 1227–54.
28. Souto EB, Zielinska A, Souto SB, Durazzo A, Lucarini M, Santini A, et al. Nanopharmaceutics: part I—clinical trials legislation and good manufacturing practices (GMP) of nanotherapeutics in clinical practice. Int. J. Mol. Sci., 2020; 21(23): 9186.
29. Costantino HR, Illum L, Brandt G, Johnson PH, Quay SC. Intranasal delivery: physicochemical and therapeutic aspects. Int. J. Pharm., 2007; 337(1–2): 1–24.
30. Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective. Drug. Deliv. Transl. Res., 2013; 3(1): 42–62.